BUZZ-Fast LNG facility shuts down, New Fortress Energy stock falls
路透社2026/10/05 16:41On October 5, shares of U.S. liquefied natural gas company New Fortress Energy (NFE.O) fell 14.3% to a historic low of $5.63. NFE stated that its Fast LNG facility was shut down due to a mechanical failure in the plant's gas turbine. The company added that it is actively working with the turbine manufacturer to restore the Fast LNG facility to operation as soon as possible. NFE expects the Fast LNG facility to resume operations in the fourth quarter. Including the decline from this trading day, the stock has fallen a cumulative 90.1% this year. (For the convenience of non-English speakers, Reuters has automated the translation of its reports into several other languages. Due to possible errors in automated translation or a lack of necessary context, Reuters does not guarantee the accuracy of translated texts and provides them solely for readers’ convenience. Reuters assumes no liability for any damages or losses resulting from the use of automated translation.)
October 5 - ** U.S. liquefied natural gas company New Fortress Energy NFE.O shares fell 14.3%, hitting a new record low of $5.63
** NFE stated that its Fast LNG facility was shut down due to a mechanical failure in a gas turbine at the site (link)
** The company added that it is actively working with the turbine manufacturer to restore the Fast LNG facility operations as soon as possible
** NFE expects the Fast LNG facility to resume operations in the fourth quarter
** Including today's decline, the stock is down 90.1% year-to-date
(To facilitate users whose native language is not English, Reuters has automated its reports into several other languages. Because automated translation may contain errors or may not include the required context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for the convenience of readers. Reuters accepts no responsibility for any damage or loss caused by the use of the automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released
October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)
Ethereum Price Prediction Eyes $3,500 Before $60K Macro Target
AI and Aerospace “Dual Engines” Launched! Goldman Sachs Targets SpaceX (SPCX.US) at $230
Goldman Sachs reiterated its “Buy” rating on SpaceX in its research report, raising the 12-month target price from $220 to $230, representing an upside potential of nearly 45% from last Friday’s closing price.
Crypto prices
More
